NASDAQ:ARQT

Arcutis Biotherapeutics Stock Insider Trading

Healthcare > Biotechnology

Buy ARQT

*Your capital is at risk

$26.27

-0.390 (-1.46%)

At Close: Jun 23, 2026

Arcutis Biotherapeutics Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be negative at -52.28. In total, the insiders bought 1.25M and sold 371.45K ARQT shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	-52.28
● Buy	1.25M shares
● Sell	371.45K shares
51% Buy Activity Negligible or No Correlation
Buy Signal Low Confidence Feb 27, 2026 Analysis Breakdown: Signal is highly questionable due to a strongly contradictory negative Insider Power Score of -52.28. Confidence increased due to high data reliability score of 100.

Historical Insider Trades

Date	Type	Person	Role	Amount
Jun 17, 2026 Sell	Common Stock S-Sale	Welgus Howard G. Director	Director	635 Value: $16.3K
Jun 15, 2026 Sell	Common Stock S-Sale	Welgus Howard G. Director	Director	4 096 Value: $100.0K
Jun 15, 2026 Buy	Stock Option (right to buy) M-Exempt	Welgus Howard G. Director	Director	2 255 Value: $19.5K
Jun 15, 2026 Buy	Stock Option (right to buy) M-Exempt	Welgus Howard G. Director	Director	1 019 Value: $8K
Jun 15, 2026 Buy	Stock Option (right to buy) M-Exempt	Welgus Howard G. Director	Director	822 Value: $5K
Jun 15, 2026 Sell	Common Stock S-Sale	Lin Sue-jean Director	Director	4 946 Value: $120.6K
Jun 15, 2026 Buy	Common Stock M-Exempt	Welgus Howard G. Director	Director	2 255 Value: $19.5K
Jun 15, 2026 Buy	Common Stock M-Exempt	Welgus Howard G. Director	Director	1 019 Value: $8K
Jun 15, 2026 Buy	Common Stock M-Exempt	Welgus Howard G. Director	Director	822 Value: $5K
Jun 05, 2026 Buy	Common Stock J-Other	Heron Patrick J	Director	0 Value: $0
Jun 05, 2026 Buy	Common Stock A-Award	Leonard Keith R Director	Director	5 778 Value: $122.7K
Jun 05, 2026 Buy	Stock Option (right to buy) A-Award	Welgus Howard G. Director	Director	16 667 Value: $353.8K
Jun 05, 2026 Buy	Common Stock A-Award	Lin Sue-jean Director	Director	5 778 Value: $122.7K
Jun 05, 2026 Buy	Stock Option (right to buy) A-Award	Heron Patrick J Director	Director	16 667 Value: $353.8K
Jun 05, 2026 Buy	Common Stock A-Award	Heron Patrick J Director	Director	5 778 Value: $122.7K
Jun 05, 2026 Buy	Common Stock A-Award	Curran Terrie Director	Director	5 778 Value: $122.7K
Jun 05, 2026 Buy	Stock Option (right to buy) A-Award	Curran Terrie Director	Director	16 667 Value: $353.8K
Jun 05, 2026 Buy	Stock Option (right to buy) A-Award	Leonard Keith R Director	Director	16 667 Value: $353.8K
Jun 05, 2026 Buy	Stock Option (right to buy) A-Award	Krishnamohan Neha Director	Director	16 667 Value: $353.8K
Jun 05, 2026 Buy	Common Stock A-Award	Krishnamohan Neha Director	Director	5 778 Value: $122.7K
Jun 05, 2026 Buy	Stock Option (right to buy) A-Award	Gilbert Halley E Director	Director	16 667 Value: $353.8K
Jun 05, 2026 Buy	Common Stock A-Award	Gilbert Halley E Director	Director	5 778 Value: $122.7K
Jun 05, 2026 Buy	Common Stock A-Award	Munshi Amit Director	Director	5 778 Value: $122.7K
Jun 05, 2026 Buy	Stock Option (right to buy) A-Award	Munshi Amit Director	Director	16 667 Value: $353.8K
Jun 05, 2026 Buy	Stock Option (right to buy) A-Award	Lin Sue-jean Director	Director	16 667 Value: $353.8K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT ARCUTIS BIOTHERAPEUTICS INC

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical foam formulation of roflumilast for the treatment of seborrheic dermatitis and scalp ...

Read Full Profile Here